Mechanisms, combination therapy, and biomarkers in cancer immunotherapy resistance

Cell Communication and Signaling, Journal Year: 2024, Volume and Issue: 22(1)

Published: June 19, 2024

Abstract Anti-programmed death 1/programmed ligand 1 (anti-PD-1/PD-L1) antibodies exert significant antitumor effects by overcoming tumor cell immune evasion and reversing T-cell exhaustion. However, the emergence of drug resistance causes most patients to respond poorly these checkpoint inhibitors (ICIs). Studies have shown that insufficient infiltration, lack PD-1 expression, deficient interferon signaling, loss antigen presentation, abnormal lipid metabolism are all considered be closely associated with immunotherapy resistance. To address in immunotherapy, a lot research has concentrated on developing combination therapy strategies. Currently, ICIs such as anti-PD-1 /PD-L1 antibody combined chemotherapy targeted been approved for clinical treatment. In this review, we analyze mechanisms anti-PD-1/PD-L1 terms microenvironment, gut microbiota, epigenetic regulation, co-inhibitory receptors. We also discuss various promising therapeutic strategies drugs, including combining therapies traditional Chinese medicine, non-coding RNAs, therapy, other ICIs, personalized cancer vaccines. Moreover, focus biomarkers predict well efficacy. Finally, suggest ways further expand application through using biomarker systems.

Language: Английский

---

Lighting Up Dual-Aptamer-Based DNA Logic-Gated Series Lamp Probes with Specific Membrane Proteins for Sensitive and Accurate Cancer Cell Identification

Analytical Chemistry, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 9, 2025

Accurate identification of cancer cells under complex physiological environments holds great promise for noninvasive diagnosis and personalized medicine. Herein, we developed dual-aptamer-based DNA logic-gated series lamp probes (DApt-SLP) by coupling a cell-classifier (DCC) with self-powered signal-amplifier (SSA), enabling rapid sensitive in blood sample. DCC is endowed two extended-aptamer based modules recognizing the cascade cell membrane receptors serves as logic gate to pinpoint particular narrow subpopulation from larger population similar cells. leverages dual-receptor co-recognition strategy enhanced specificity performing matching operation between aptamer receptor twice on membranes. SSA signal converter attached at end that changes process into detectable signals, well amplifier output amplified signals using simple efficient hybridization chain reaction. Unique those who are multicomponent systems, DApt-SLP an all-in-one compact nanodevice, exhibiting nuclease-degradation resistance targeting ability. In vitro feasibility, imaging, flow cytometry analysis showed system successfully operated buffered solution environment precisely differentiated target large populations Benefiting its integrated design single-step high sensitivity accuracy, practical tool medicine biomedical engineering.

Language: Английский

---

Mesenchymal stem cells - the secret agents of cancer immunotherapy: Promises, challenges, and surprising twists

Oncotarget, Journal Year: 2024, Volume and Issue: 15(1), P. 793 - 805

Published: Nov. 22, 2024

// Theia Minev 1 , Shani Balbuena Jaya Mini Gill Francesco M. Marincola 2 Santosh Kesari 3 and Feng Lin CureScience Institute, San Diego, CA 92121, USA Sonata Therapeutics, Boston, MA 02472, Department of Translational Neurosciences, Pacific Neuroscience Institute Providence Saint John's Health Center, Cancer Santa Monica, 90404, Correspondence to: Lin, email: [email protected] Keywords: mesenchymal stem cells; genetic engineering; cancer immunotherapy; cell homing; delivery Received: August 20, 2024 Accepted: November 05, Published: 22, Copyright: © et al. This is an open access article distributed under the terms Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, reproduction in any medium, provided original author source are credited. ABSTRACT Mesenchymal cells (MSCs) recognized for their immunomodulatory capabilities, tumor-homing abilities, capacity to serve as carriers therapeutic agents. review delves into role adoptively transferred MSCs tumor progression, interactions with microenvironment, use delivering anti-cancer drugs, oncolytic viruses, material. It also addresses challenges limitations associated MSC therapy, such variability preparations potential tumorigenic effects emphasizing need advanced engineering personalized approaches enhance efficacy. The concludes optimistic outlook on future MSC-based therapies, underscoring promise develop effective treatments.

Language: Английский

---

Monoclonal antibodies: From magic bullet to precision weapon

Molecular Biomedicine, Journal Year: 2024, Volume and Issue: 5(1)

Published: Oct. 11, 2024

Monoclonal antibodies (mAbs) are used to prevent, detect, and treat a broad spectrum of non-communicable communicable diseases. Over the past few years, market for mAbs has grown exponentially with an expected compound annual growth rate (CAGR) 11.07% from 2024 (237.64 billion USD estimated at end 2023) 2033 (679.03 by 2033). Ever since advent hybridoma technology introduced in 1975, antibody-based therapeutics were realized using murine which further progressed into humanized fully human antibodies, reducing risk immunogenicity. Some benefits over conventional drugs include drastic reduction chances adverse reactions, interactions between drugs, targeting specific proteins. While very efficient, their higher production costs impede process commercialization. However, cost factor been improved developing biosimilar as affordable versions therapeutic antibodies. Along recent advancements innovations antibody engineering have helped will furtherly help design bio-better efficacy than ones. These novel mAb-based set revolutionize existing drug therapies wide diseases, thereby meeting several unmet medical needs. This review provides comprehensive insights current fundamental landscape development applications key factors influencing future projections, advancement, incorporation such promising immunotherapeutic candidates confrontation approach against list rationalistic mentioning any limitations facing this field.

Language: Английский

---

A Comprehensive Review of Evidence and Challenges in Switching from Originator Drugs to Biosimilars of Monoclonal Antibodies: Focus on Rituximab and Trastuzumab

Journal of Drug Delivery and Therapeutics, Journal Year: 2025, Volume and Issue: 15(2), P. 149 - 155

Published: Feb. 15, 2025

Objective: The primary objective of the document is to conduct a comprehensive review clinical, economic, and regulatory evidence regarding transition from originator drugs biosimilars monoclonal antibodies, focusing specifically on rituximab trastuzumab. aims analyze data biosimilar usage, assess barriers adoption, explore potential strategies overcome challenges, with ultimate goal improving healthcare sustainability accessibility. Data source Study selection: study selection includes clinical trials, economic analyses, reviews It focuses phase 3 cost-effectiveness studies, post-marketing surveillance for assessing safety, efficacy, adoption barriers. Real-world guidelines agencies such as EMA FDA are also considered. Summary: article antibody biosimilars, Topics evidence, benefits, include issues related immunogenicity concerns perceived physician-patient acceptance. While offering potentially cost-effective treatments cancer, further research, harmonization regulations, education will allow this value be realized across more patients, improved outcomes. Conclusion: like trastuzumab, enhances treatment accessibility affordability. Clinical supports their safety but challenges remain, including concerns, differences, stakeholder perceptions. Addressing these through global can optimize sustainability. Keywords: Rituximab, Trastuzumab, Biosimilars, Switching, Monoclonal Antibodies.

Language: Английский

---

Advances with radiopharmaceutical therapy in cancer

Elsevier eBooks, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Language: Английский

---

Antibody–drug conjugates: prospects for the next generation

Drug Discovery Today, Journal Year: 2024, Volume and Issue: 29(12), P. 104241 - 104241

Published: Nov. 13, 2024

The concept of a 'magic bullet' was first introduced by Paul Ehrlich in the early 1900s, he foresaw advent targeted therapies and specific killing harmful cells and/or microorganisms. However, these were only used clinic after second half 20th century with development monoclonal antibodies. To date, 13 antibody-drug conjugates (ADCs) are commercially available. Many advances have been made modifying one or several three main components an ADC, namely antibody, cleavable non-cleavable linker payload, integrating conjugation chemistry. Despite efforts, some problems emerged thus limit their effectiveness. New strategies could overcome identify next generation ADC.

Language: Английский

---

Assessment of mirvetuximab soravtansine immunogenicity in patients with folate receptor alpha-positive ovarian cancer

Bioanalysis, Journal Year: 2024, Volume and Issue: 16(21-22), P. 1101 - 1113

Published: Oct. 8, 2024

Aim: The aim of this research was to evaluate the immunogenicity mirvetuximab soravtansine (MIRV), an antibody-drug conjugate in patients with folate receptor alpha-positive ovarian cancer across four clinical studies.

Language: Английский

---